Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment

Launched by FUDAN UNIVERSITY · Aug 21, 2019

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of surgery for patients with pancreatic neuroendocrine tumors that have spread to other parts of the body, especially the liver. The goal is to find out if patients who receive a specific treatment before surgery (called induction systemic treatment) can benefit from having both their primary tumor in the pancreas and any liver tumors removed at the same time. Participants will have a choice to decide whether they want to undergo surgery or continue with standard treatments.

To be eligible for this trial, patients must have a confirmed diagnosis of a neuroendocrine tumor located in the pancreas that has spread to other areas, making surgery not immediately possible at the time of diagnosis. They should be in generally good health and able to undergo treatment with a good chance of recovery. However, patients with certain types of tumors or other health conditions may not qualify. Those who join the study can expect to work closely with their healthcare team to determine the best treatment path for them. This trial is currently recruiting participants of all genders, aged between 65 and 74 up to 29 and 219.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Biopsy-proven neuroendocrine tumor
• • 2. primary site in pancreas
• • 3. Advanced disease with lymph node or distant metastases (N1, M1) cannot undergoing cytoreduction by surgery/local ablative therapy at the diagnosis
• • 4. curative intent of all therapies possible
• • 5. ECOG 0-2
• Exclusion Criteria:
• • 1. Undifferentiated neuroendocrine carcinoma or mixed neuroendocrine carcinoma secondary tumor
• • 2. functioning NET or advanced carcinoid heart disease
• • 3. part of hereditary syndrome, such as MEN1, VHL
• • 4. do not willing to receive systemic treatment
• • 5. diagnosed with other cancer within 5 years